Takeda Pharmaceutical: Soticlestat Narrowly Missed Primary Endpoint of Reduction From Baseline in Convulsive Seizure Frequency as Compared to Placebo
武田製藥:與安慰劑相比,索地利斯塔未能達到抽搐發作頻率基線的主要終點
Takeda Pharmaceutical: Soticlestat Narrowly Missed Primary Endpoint of Reduction From Baseline in Convulsive Seizure Frequency as Compared to Placebo
武田製藥:與安慰劑相比,索地利斯塔未能達到抽搐發作頻率基線的主要終點
譯文內容由第三人軟體翻譯。